Search Within

GDMT, Medicine

Formats
  1. Journal Article (935)
  2. Meeting Abstract (836)
  3. Review (49)
  4. Book Section (38)
  5. Editorial (30)
  6. Guidelines (19)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1915)
  2. Department of Medicine (1904)
  3. Solid Tumor Oncology Division (1904)
  4. Gynecologic Medicine Service (1864)
  5. Surgery (585)
  6. GDMT, Surgery (467)

More Groups

People
  1. Carol Aghajanian (616)
  2. Martee Hensley (290)
  3. Nadeem Abu-Rustum (281)
  4. Roisin O'Cearbhaill (275)
  5. Vicky Makker (270)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (78)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Journal of Clinical Oncology (421)
  2. Gynecologic Oncology (419)
  3. International Journal of Gynecological Cancer (156)
  4. Annals of Oncology (107)
  5. Clinical Cancer Research (65)
  6. Cancer (37)

More Publications

Publishers
  1. American Society of Clinical Oncology (453)
  2. Elsevier B.V. (443)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (141)
  5. Oxford University Press (130)
  6. Elsevier Inc. (83)

More Publishers

Results (1915)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Voices of women with low-grade serous ovarian cancer: Results from a multinational survey
    Meeting Abstract

    Sun, C.; Andrews, N.; Ludemann, J.; Larsen, E.; MacKay, C.; de Fazio, A.; Gaillard, S.; Gourley, C.; Carey, M.; Fader, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • nab-Sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer: A phase II, open-label, single-arm, prospective, multicenter study
    Meeting Abstract

    Dockery, L.; Slomovitz, B.; Priebe, A.; Green, A.; Mathews, C.; Musa, F.; Puechl, A.; Birrer, M.; Spirtos, N.; Ding, L.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update
    Meeting Abstract

    Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; O'Cearbhaill, R.; Bouberhan, S.; Moore, K.; Hou, J.; Hamilton, E.; Yoo, S. Y.; Wang, B.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer
    Meeting Abstract

    Girda, E.; Makker, V.; Marth, C.; Van Gorp, T.; Mirza, M.; Shapira-Frommer, R.; Suttner, L.; Groisberg, R.; Jin, F.; O'Malley, D.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    Meeting Abstract

    Pothuri, B.; Valabrega, G.; Oaknin, A.; Graybill, W.; Sánchez, A. B.; McCormick, C.; Baurain, J. F.; Tinker, A.; Denys, H.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST)
    Meeting Abstract

    Aghajanian, C.; Washington, C.; Moore, K.; Krivak, T.; Mathews, C.; Philip, T.; Konecny, G.; Fleming, G.; Martin, N.; Smith, G.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Prognostic value of aggressive histology in surgically-staged, clinically uterine-confined endometrial carcinoma
    Meeting Abstract

    Dagher, C.; Mueller, J.; Abu-Rustum, N.; Sonoda, Y.; Momeni-Boroujeni, A.; Makker, V.; O'Cearbhaill, R.; Alektiar, K.; Leitao, M.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
    Meeting Abstract

    Grisham, R.; Monk, B.; Nieuwenhuysen, E.; Moore, K.; Fabbro, M.; O'Malley, D.; Oaknin, A.; Thaker, P.; Oza, A.; Colombo, N.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Intraperitoneal therapy with engineered Newcastle disease virus encoding interleukin-12 in combination with PD-1 blockade for ovarian cancer
    Meeting Abstract

    Kahn, R.; Ozsoy, M. A.; Green, H.; Gill, K.; Praiss, A.; Pesci, G.; Burman, B.; Brodeur, M.; Bhaloo, S. I.; Abu-Rustum, N.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Whole-genome sequencing-based genomic characterization of uterine serous carcinoma
    Meeting Abstract

    Andres, S.; Brown, D.; Da Cruz Paula, A.; Aghajanian, C.; Abu-Rustum, N.; Ellenson, L.; Weigelt, B.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save